donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
03347 Tigermed
93.650
+1.050+1.13%
YOY
Do not show
Hide blank lines
(Q3)2022/03/31(FY)2021/12/31(Q9)2021/09/30(Q6)2021/06/30
Turnover
101.55% 1.82B 63.32% 5.21B 47.58% 3.4B 41.62% 2.06B
Operating income
101.55% 1.82B 63.32% 5.21B 47.58% 3.4B 41.62% 2.06B
Cost of sales
-- -- -75.58% -2.97B -- -- -44.51% -1.09B
Operating expenses
-132.28% -1.11B -75.58% -2.97B -52.5% -1.81B -44.51% -1.09B
Gross profit
66.79% 705.85M 49.54% 2.25B 42.35% 1.59B 38.5% 966.92M
Selling expenses
-21.74% -38.51M -33.98% -129.4M -37.68% -95.85M -67.65% -66.66M
Administrative expenses
-39.22% -158.95M -38.44% -554.81M -42.05% -388.65M -32.56% -246.68M
Research and development expenses
-21.33% -56.99M -35.23% -211.83M -39.77% -154.81M -28.48% -93.03M
Revaluation surplus
-71.44% 125.13M -- -- 18.63% 1.12B -- --
-Changes in the fair value of other assets
-71.44% 125.13M -- -- 18.63% 1.12B -- --
Impairment and provision
-105.74% -11.72M -342.44% -24.43M -242.33% -17.8M -76.42% -10.25M
-Other impairment is provision
-105.74% -11.72M -342.44% -24.43M -242.33% -17.8M -76.42% -10.25M
Operating interest expense
-51.3% 30.32M -- -- 227.14% 175.59M -- --
Special items of operating profit
90.38% 59.24M 67.65% 2.37B 32.32% 117.29M 47.36% 1.15B
Operating profit
-13.48% 654.38M 62.67% 3.7B 51.16% 2.34B 44.78% 1.7B
Financing cost
-- -- 50.94% -24.91M -- -- 76.58% -7.94M
Share of profits of associates
-- -- 509.01% 14.35M -- -- 116.94% 723K
Special items of earning before tax
87.04% 1.62M -- -- -47.93% -4.94M -- --
Earning before tax
-13.36% 656M 66.17% 3.69B 51.17% 2.34B 49% 1.7B
Tax
-137.02% -82.03M -54.38% -292.86M -5.57% -150.18M -14.53% -103.53M
After-tax profit from continuing operations
-20.56% 573.97M 67.28% 3.4B 55.79% 2.19B 51.97% 1.59B
Earning after tax
-20.56% 573.97M 67.28% 3.4B 55.79% 2.19B 51.97% 1.59B
Minority profit
-79.2% 55.55M 85.35% 517.54M 376.29% 404.67M 800.48% 334.27M
Profit attributable to shareholders
13.82% 518.42M 64.4% 2.88B 35.13% 1.78B 24.51% 1.26B
Basic earnings per share
15.38% 0.6 50.91% 3.32 19.88% 2.05 6.62% 1.45
Diluted earnings per share
51.14% 3.31 6.67% 1.44
Currency Unit
CNYCNYCNYCNY
Accounting Standards
CAS (2007)IASCAS (2007)IAS
Audit Opinions
--Unqualified Opinion----
Auditor
--Hong Kong Lixin Dehao Accounting firm Co., Ltd.----

Q6, Q9, and FY are cumulative quarterly reports: Q6 is the interim report; Q9 is third quarter report; FY is the annual report.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Hangzhou Tiger Pharmaceutical Technology Co., Ltd. is a Chinese holding company engaged in providing clinical trial services for new drug research and development. The company operates two branches. The Clinical trial Technical Services Division provides clinical trial operation services and medical translation services to biopharmaceutical and medical device companies to help them conduct clinical trials of innovative drugs, generic drugs and medical devices. The Clinical trial related Services and Laboratory Services Division is engaged in providing analytical services, such as data management and statistical analysis; logistical and executive support services, such as clinical trial site management; administrative assistance, such as patient recruitment; and consulting services. The division, through its subsidiaries, also provides laboratory services for preclinical and clinical development phases. The company operates in both domestic and overseas markets.
CEO: Xiaoping Ye
Market: Hong Kong motherboard
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...